drugset / Trial / NCT02633930

Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy

NCT02633930

Phase 4 Completed 566 enrolled Xijing Hospital of Digestive Diseases
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims at evaluating efficacy and safety of berberine-containing quadruple therapy(berberine, lansoprazole, bismuth and amoxicillin) versus clarithromycin-containing quadruple therapy (clarithromycin,lansoprazole, bismuth and amoxicillin) in H. pylori eradication. It is hypothesized that berberine-containing quadruple therapy is non-inferior to clarithromycin-containing quadruple therapy. Patients with confirmed H. pylori positive status will be randomized to one of the treatments described above. At week 2 and 6 follow-up visits, a urea breath test(UBT) will be performed to confirm eradication.

Timeline

Start
2015-12
Primary completion
2016-06
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Berberine Traditional medicine (herbal / TCM) 300 mg Oral
Comparator Clarithromycin Small molecule 500 mg Oral
Background Amoxicillin Other / unclassified 1000 mg Oral
Background Bismuth Potassium Citrate Unknown 220 mg Oral
Background Lansoprazole Other / unclassified 30 mg Oral